This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NovaBay Pharmaceuticals Reports Activity Of Aganocide NVC-422 Against Deadly "Superbug" Producing NDM-1 (New Delhi Metallo-beta-lactamase-1)

NVC-422 Also Shown Effective Against Six Other Highly Drug-Resistant Pathogens

EMERYVILLE, Calif., Jan. 6, 2011 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that in tests conducted at a third-party laboratory, NovaBay's lead Aganocide, NVC-422 has shown in vitro activity against the "superbug" New Delhi Metallo-beta-lactamase-1 (NDM-1)-encoded Klebsiella pneumoniae at a very low concentration of 2 mg/mL. In comparison, Imipenem, which is a mainstay antibiotic for the treatment of antibiotic-resistant bacterial infections, is not effective against NDM-1-encoded strains. 

NovaBay currently is engaged in testing additional strains of E. coli and K. pneumoniae encoded with NDM-1 gene. The company previously reported that NVC-422 was effective in vitro against resistance phenotypes of E. coli and K. pneumoniae, including extended-spectrum beta-lactamase (ESBL) and multidrug-resistant (MDR) strains. NovaBay intends to publish and present the full data set at the upcoming Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

K. pneumoniae and E. coli have been identified as a cause of severe infections, sepsis and possibly death. In a number of non-systemic/topical opportunities of interest to NovaBay's development, both these superbugs are major risk factors. These include catheter-associated urinary tract infections (UTIs); respiratory tract infections, including those caused by cystic fibrosis; and wound infections, including venous stasis, pressure ulcers and diabetic ulcers.

Dr. Ron Najafi, CEO of NovaBay Pharmaceuticals, said, "We were very excited to see the in vitro activity results of NVC-422 against NDM-1 strains. In fact, we have collected data indicating that NVC-422 is also effective in vitro against all six highly resistant pathogens know as ESKAPE:  Enterococcus faecium, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter which are the cause of much of the hospital-associated Infections today. We intend to translate this activity into products that will benefit patients in need. Both UTI and chronic non-healing wounds will be the future breeding ground for NDM-1 producing bacteria."

NovaBay is currently engaged in a Phase 2 human trial for urinary catheter blockage and encrustation (UCBE) leading to urinary tract infections, and the company and its partner Galderma S.A. are engaged in the clinical development of its lead compound for the treatment of impetigo, a highly contagious infection with potential benefit in chronic wound care management.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs